噻吗咯尔杂质E | 1026075-53-5

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 噻吗咯尔杂质E
• 英文名称: Timolol maleate ester
• 英文别名: (Z)-4-[(2S)-1-(tert-butylamino)-3-[(4-morpholin-4-yl-1,2,5-thiadiazol-3-yl)oxy]propan-2-yl]oxy-4-oxobut-2-enoic acid
• CAS: 1026075-53-5
• 化学式: C₁₇H₂₆N₄O₆S
• 分子量: 414.5
• InChiKey: MGIAXRFZDNBKRF-RXNFCKPNSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  28
• 可旋转键数：
  11
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.65
• 拓扑面积：
  151
• 氢给体数：
  2
• 氢受体数：
  11

文献信息

• [EN] DRUGS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS<br/>[FR] COMPOSÉS ET COMPOSITIONS POUR LE TRAITEMENT DE TROUBLES OCULAIRES
  申请人：GRAYBUG VISION INC

  公开号：WO2018175922A1

  公开（公告）日：2018-09-27

  The present invention provides new prodrugs of therapeutically active compounds, including oligomeric prodrugs, and compositions to treat medical disorders, for example glaucoma, a disorder or abnormality related to an increase in intraocular pressure (IOP), a disorder requiring neuroprotection, age-related macular degeneration, or diabetic retinopathy.

  本发明提供了治疗活性化合物的新前药，包括寡聚前药，以及用于治疗医学疾病的组合物，例如青光眼，一种与眼压增高有关的疾病或异常，需要神经保护的疾病，年龄相关性黄斑变性，或糖尿病性视网膜病变。
• Extended release microparticles and suspensions thereof for medical therapy
  申请人：Graybug Vision, Inc.

  公开号：US11160870B2

  公开（公告）日：2021-11-02

  An improved microparticle or lyophilized or otherwise reconstitutable microparticle composition thereof for medical therapy, including ocular therapy.

  一种用于医疗（包括眼科治疗）的改良微粒或冻干或可重组微粒组合物。
• EP2506865B1
  申请人：——

  公开号：EP2506865B1

  公开（公告）日：2015-04-01
• DRUGS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS
  申请人：Graybug Vision, Inc.

  公开号：EP3600324A1

  公开（公告）日：2020-02-05
• Method for stabalizing timolol concentration
  申请人：Grabowski Philip Paul

  公开号：US20050048122A1

  公开（公告）日：2005-03-03

  A novel method for stabilizing timolol concentration in a container containing an aqueous composition comprising timolol is disclosed. The container is made of a pharmaceutically acceptable, moisture-permeable material. This method comprises the step of enclosing the container in a secondary package. The secondary package is made of a pharmaceutically acceptable material having a low permeability to moisture. A medicinal product comprising an aqueous composition comprising timolol is also disclosed. The composition is packaged in a container made of a pharmaceutically acceptable, moisture-permeable material. The container is enclosed in a secondary package, which is made of a pharmaceutically acceptable material having a low permeability to moisture.